LncRNAs and miRNAs participate in determination of sensitivity of cancer cells to cisplatin

• Published in: Experimental and molecular pathology Vol. 123; p. 104602
• Main Authors: Taheri, Mohammad, Shoorei, Hamed, Tondro Anamag, Farhad, Ghafouri-Fard, Soudeh, Dinger, Marcel E.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Inc 01.12.2021
• Subjects: Apoptosis - drug effects; Cell Proliferation - drug effects; chemoresistance; Cisplatin; Cisplatin - adverse effects; Cisplatin - therapeutic use; Drug Resistance, Neoplasm - genetics; Gene Expression Regulation, Neoplastic - drug effects; Humans; lncRNA; MicroRNAs - genetics; miRNA; Neoplasms - drug therapy; Neoplasms - genetics; Progression-Free Survival; RNA, Long Noncoding - genetics; miRNA; chemoresistance; lncRNA; Cisplatin

Cisplatin is an extensively used chemotherapeutic substance for various types of human malignancies including sarcomas, carcinomas and lymphomas. Yet, the vast application of this drug is hampered by the emergence of chemoresistance in some treated patients. Several mechanisms such as degradation of...